A randomised, double-blind controlled trial of mometosone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN03885092

Enrollment

120

Registered

2010-07-07

Start date

2009-11-02

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: National Cancer Research Network

Interventions

Placebo or mometasone furoate. Assessments are taken at baseline, day 8, 15, 21, 29, 36 and 43. Study entry: single randomisation only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or over, either sex 2. Receiving 40 Gy 15 fractionated, 3 week radical radiotherapy to the breast or chest wall 3. Patient provides informed consent to participate in the study and completes follow up

Exclusion criteria

Exclusion criteria: 1. Skin involvement of disease 2. Untreated bacterial, fungal or viral skin lesions 3. Inability to self administer creams

Design outcomes

Primary

Measure	Time frame
Change in visual skin assessment	—

Secondary

Measure	Time frame
1. Objective skin assessment 2. Changes in quality of life measures	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026